This polymorphism probably triggers NAFLD and CAD's pathogenesis in type 2 diabetic patients by altering the PGC-1α interaction with other transcription factors and affecting oxidative stress and lipid metabolism [6, 70]. This evidence concerns the gene PPARGC1A and coronary artery disorder.